对于转移性染细胞瘤和偏角质瘤的患者进行全身治疗
Alessa Fischer1, Jaydira Del Rivero2, Katharina Wang3
1Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH), Zurich CH-8091, Switzerland.
Best practice & research. Clinical endocrinology & metabolism
|January 29, 2025
概括
转移性染细胞瘤和偏角细胞瘤是罕见的神经内分泌瘤,往往会导致严重的并发症. 最近的进展提供了超越传统化疗的新疗法,改善了患者的治疗结果.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 乳色细胞瘤和偏角细胞瘤是罕见的神经内分泌瘤,起源于偏角细胞.
- 这些瘤经常会导致心血管和胃肠道问题,原因是过度分泌catecholamine.
- 大约三分之一的这些瘤转移,主要到淋巴结,骨,肝脏和肺部,影响生存率.
研究的目的:
- 审查新型全身疗法的疗效和安全性,用于转移性染细胞瘤和偏角细胞瘤.
- 介绍放射性药物和氨酸激酶抑制剂前性临床试验的发现.
- 概述这些罕见瘤新兴疗法的潜在好处.
主要方法:
- 对未来临床试验的审查.
- 对放射性药物和氨酸激酶抑制剂的数据分析.
- 目前正在研究的新型治疗剂的评估.
主要成果:
- 传统的治疗方法包括化学疗法 (cyclophosphamide,vincristine,dacarbazine) 和-131-metaiodobenzylguanidine. 这两种药物可以帮助治疗.
- 最近的研究导致了基于生物化学和分子特征的新疗法.
- 在过去的十年中,引入了创新的全身疗法.
结论:
- 显著的科学进步已经扩大了转移性染细胞瘤和偏角细胞瘤的治疗选择.
- 放射性药物和氨酸激酶抑制剂在临床试验中显示出有希望的结果.
- 目前正在进行的研究继续确定和评估新型疗法,以改善患者的生存和管理.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Adrenergic Agonists: Therapeutic Uses
722
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
722
Drugs Acting on Autonomic Ganglia: Blockers
949
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
949
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131


